XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today congratulated Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg, a director and founder of XPhyto, is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (“UoA”) and the founder and director of the Drug Development and Innovation Centre (“DDIC”), UoA. The CSPS Award is bestowed upon an individual who has demonstrated leadership in advancing the cause of pharmaceutical research and development in Canada. Prof. Dr. Loebenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis and leishmanasis. Dr. Loebenberg serves on XPhyto’s board of directors and leads its psychedelic medicine program with a multi-pronged approach including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue engineering, and clinical validation.
To view the full press release, visit https://ibn.fm/mbGXU
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
